Sharon Bio-Medicine Ltd:-Buy/sell :multibagger

Scripscan:Sharon Bio-Medicine Ltd

BSE code:532908

cmp:290

Story:Sharon Bio-Medicine Ltd (SBML) is engaged in the manufacturing of Active Pharma Ingredients (API), Intermediates and Formulations (own brands). It has a diversified product portfolio with presence mainly in acute therapies such as anti-infectives and anti-biotics. SBML also has presence in chronic therapies such as diabetes and cardiovascular. In JY08 (financial year ends in June), it commenced its formulations business with manufacturing of its own brands targeting the domestic market. During JY10, the contribution of sales from formulations business to the total sales was 34.4%. SBML has four manufacturing facilities,three at Taloja inMaharashtra(two for manufacture of API and intermediates and one for Toxicology studies) and one at Dehradun in Uttaranchal for manufacturing of formulation products. During JY10, the Dehradun plant received UKMHRA certification. In addition, it has three R&D centers located at its manufacturing facilities. SBML has set up a R&D unit named sa- FORD (sanctuary for Research and Development Laboratories), which is a state-of-the-art animal testing and breeding facility atTaloja.SBML is committed to leverage the lucrative opportunities coming up by forward integrating into contract formulation research and manufacturing, entering high-margin, highly-sensitive oncology therapeutic segment, invested in new state-of-the-art API facilities targeting the regulated markets, expanding product pipelines by addressing the growing anti-depressant and antiretrovials therapeutic segments, filing DMFs for its key products, strengthening R&D capabilities, vigorously improving productivity in pursuit of operational excellence in all its activities and rank amongst the most efficient and effective companies in this sector. It has also received new approvals for its R&D facilities, which could reap benefits going ahead. This could help SBML to become a fully integrated company, emerge as a suitable partner for long-term relationships and cumulatively strengthen its potential to deliver substantial upside for all its stakeholders.Even though SBML is trading at a higher valuation than its peers we believe there is scope for further appreciation.The stock is currently trading at Rs.290 (~7.8x JY12 (E) EPS of Rs.37.7).A good hold at present prices.

Share this nice post:
PDF Printer    Send article as PDF   

Share This Post

Recent Articles

Leave a Reply

Powered by WinTrader · Designed by REACOMS International